Bleeding Patterns After Nexplanon Insertion
Approximately 78% of Nexplanon users will experience some form of spotting or continued menstrual bleeding, with only 22% achieving complete amenorrhea. 1, 2
Specific Bleeding Pattern Breakdown
Based on pooled analysis from 11 clinical trials of etonogestrel implant users, the bleeding patterns break down as follows:
- 22% experience amenorrhea (no bleeding)
- 34% have infrequent spotting (less than 3 bleeding episodes per 90 days)
- 7% report frequent bleeding (more than 5 episodes per 90 days)
- 18% experience prolonged bleeding (episodes lasting >14 days)
This means 78% of patients will have some form of bleeding or spotting, while only 22% will have no bleeding at all. 1
Detailed Clinical Data from FDA Label
The FDA-approved drug label provides granular data on bleeding patterns over 90-day intervals 2:
Days of bleeding/spotting per 90-day period:
- 0 days: 17-24% of patients
- 1-7 days: 12-15% of patients
- 8-21 days: 30-37% of patients
- >21 days: 33-35% of patients
Average bleeding burden: Women experienced 17.7 days of bleeding or spotting every 90 days (approximately 20% of days).
Predictive Value of Early Bleeding Patterns
The bleeding pattern in the first 3 months strongly predicts future patterns. Women with favorable bleeding initially (amenorrhea, infrequent, or normal frequency without prolonged bleeding) have an 84.6% chance of maintaining favorable patterns, while those with unfavorable initial patterns have approximately 40-50% chance of improvement. 3, 4
Clinical Implications
Pre-Insertion Counseling Priorities
Counsel patients that:
- Most women (78%) will experience some bleeding changes
- The first 3 months predict long-term patterns
- Bleeding irregularities are not harmful
- Heavy or prolonged bleeding is uncommon (occurs in <20%)
Risk Factors for Bothersome Bleeding
Patients at higher risk for problematic bleeding include those with 5:
- Previously irregular menses (OR 1.36-1.41)
- Seeking implant primarily for menstrual management (OR 1.67)
- No prior progestin injection or implant use
Management Approach
For irregular bleeding: If no underlying pathology (pregnancy, STD, uterine conditions), consider 1:
- NSAIDs for 5-7 days during bleeding episodes
- Low-dose combined oral contraceptives or estrogen for 10-20 days (if medically eligible)
Important caveat: Medication management of bleeding is associated with nearly 2-fold higher discontinuation rates at 1 year (HR 1.98), though over 50% of treated patients still continue use for 3 years. 5
For amenorrhea: Reassurance only—no treatment needed. Rule out pregnancy if pattern changes abruptly. 1
Discontinuation Rates
Bleeding irregularities account for 11.1% of discontinuations, with irregular bleeding (10.8%) being the primary reason rather than amenorrhea (0.3%). 2 Initial favorable bleeding patterns result in significantly lower discontinuation rates: 3.7% vs 12.7% in year 1, and 2.5% vs 16.5% in year 2. 3